ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The graphics card designer and artificial intelligence developer Nvidia has invested $50 million in Recursion, an AI-based drug discovery company. The firms will also work together to optimize Recursion’s AI models for biology and chemistry in drug discovery and distribute them via Nvidia’s cloud services. Recursion recently acquired Cyclica and Valence Discovery, two chemistry-based AI developers, to broaden its biology-based drug discovery platform. The firm claims that it now has a biological and chemical dataset exceeding 23 petabytes and 3 trillion searchable gene and compound relationships. Nvidia introduced a generative drug discovery AI cloud service called BioNeMo earlier this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X